Multicenter phase II trial of neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin for HER2-positive operable breast cancer: KBOG-1204 trial
Phase 2
- Conditions
- breast cancer
- Registration Number
- JPRN-UMIN000010227
- Lead Sponsor
- Kanagawa Breast Oncology Group (KBOG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) drug allergy 2) severe complications (malignant hypertension, congestive heart failure, coronary heart disease, myocardial infarction (onset within 6 months), arrhythmia (treated), infectious disease, bleeding tendency, etc) 3) feber, infection 4) peripheral neuropathy 5) pleural effusion, pericardial effusion 6) active double cancer 7) inflammatory breast cancer 8) bilateral breast cancer, male breast cancer 9) pregnancy 10) severe edema 11) interstitial pneumonia, fibrous lung disease 12) steroid-using patients 13) psychosomatic disease 14) unsuitable patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method